{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T12:41:33Z","timestamp":1765370493617,"version":"3.28.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T00:00:00Z","timestamp":1721088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T00:00:00Z","timestamp":1721088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s00277-024-05888-5","type":"journal-article","created":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T06:01:51Z","timestamp":1721109711000},"page":"4145-4153","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic value of 18F-FDG PET\/CT in patients with relapsed multiple myeloma"],"prefix":"10.1007","volume":"103","author":[{"given":"Yue-Hong","family":"Guo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ai-Jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-Wei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min-Fu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,16]]},"reference":[{"key":"5888_CR1","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, Tuazon S, Gopal AK, Libby EN (2022) Diagnosis and management of multiple myeloma: a review. JAMA 327:464\u2013477. https:\/\/doi.org\/10.1001\/jama.2022.0003","journal-title":"JAMA"},{"key":"5888_CR2","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","volume":"32","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, Delforge M, H\u00e1jek R, Schjesvold F, Cavo M, Goldschmidt H, Facon T, Einsele H, Boccadoro M, San-Miguel J, Sonneveld P, Mey U, EHA Guidelines Committee (2021) Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020. Ann Oncol 32:309\u2013322. https:\/\/doi.org\/10.1016\/j.annonc.2020.11.014","journal-title":"Ann Oncol"},{"key":"5888_CR3","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/ajh.26590","volume":"97","author":"SV Rajkumar","year":"2022","unstructured":"Rajkumar SV (2022) Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol 97:1086\u20131107. https:\/\/doi.org\/10.1002\/ajh.26590","journal-title":"Am J Hematol"},{"key":"5888_CR4","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.2967\/jnumed.122.264972","volume":"64","author":"F Kraeber-Bod\u00e9r\u00e9","year":"2023","unstructured":"Kraeber-Bod\u00e9r\u00e9 F, Jamet B, Bezzi D, Zamagni E, Moreau P, Nanni C (2023) New Developments in Myeloma Treatment and Response Assessment. J Nucl Med 64:1331\u20131343. https:\/\/doi.org\/10.2967\/jnumed.122.264972","journal-title":"J Nucl Med"},{"key":"5888_CR5","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41408-022-00695-5","volume":"12","author":"S Kumar","year":"2022","unstructured":"Kumar S, Baizer L, Callander NS, Giralt SA, Hillengass J, Freidlin B, Hoering A, Richardson PG, Schwartz EI, Reiman A, Lentzsch S, McCarthy PL, Jagannath S, Yee AJ, Little RF, Raje NS (2022) Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee. Blood Cancer J 12:98. https:\/\/doi.org\/10.1038\/s41408-022-00695-5","journal-title":"Blood Cancer J"},{"key":"5888_CR6","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1182\/bloodadvances.2022007052","volume":"6","author":"C Charalampous","year":"2022","unstructured":"Charalampous C, Goel U, Broski SM, Dingli D, Kapoor P, Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Buadi F, Hwa L, Leung N, Lin Y, Gonsalves WI, Kourelis TV, Warsame R, Fonder A, Hobbs M, Binder M, Kyle RA, Rajkumar SV, Kumar SK (2022) Utility of PET\/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma. Blood Adv 6:2763\u20132772. https:\/\/doi.org\/10.1182\/bloodadvances.2022007052","journal-title":"Blood Adv"},{"key":"5888_CR7","doi-asserted-by":"publisher","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","volume":"20","author":"J Hillengass","year":"2019","unstructured":"Hillengass J, Usmani S, Rajkumar SV, Durie BGM, Mateos MV, Lonial S, Joao C, Anderson KC, Garc\u00eda-Sanz R, Riva E, Du J, van de Donk N, Berdeja JG, Terpos E, Zamagni E, Kyle RA, San Miguel J, Goldschmidt H, Giralt S, Kumar S, Raje N, Ludwig H, Ocio E, Schots R, Einsele H, Schjesvold F, Chen WM, Abildgaard N, Lipe BC, Dytfeld D, Wirk BM, Drake M, Cavo M, Lahuerta JJ, Lentzsch S (2019) International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol 20:e302\u2013e312. https:\/\/doi.org\/10.1016\/S1470-2045(19)30309-2","journal-title":"Lancet Oncol"},{"key":"5888_CR8","doi-asserted-by":"publisher","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","volume":"18","author":"M Cavo","year":"2017","unstructured":"Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, Hillengass J, Engelhardt M, Usmani SZ, Vesole DH, San-Miguel J, Kumar SK, Richardson PG, Mikhael JR, da Costa FL, Dimopoulos MA, Zingaretti C, Abildgaard N, Goldschmidt H, Orlowski RZ, Chng WJ, Einsele H, Lonial S, Barlogie B, Anderson KC, Rajkumar SV, Durie BGM, Zamagni E (2017) Role of 18F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol 18:e206\u2013e217. https:\/\/doi.org\/10.1016\/S1470-2045(17)30189-4","journal-title":"Lancet Oncol"},{"key":"5888_CR9","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1002\/ajh.25846","volume":"95","author":"FI Baffour","year":"2020","unstructured":"Baffour FI, Glazebrook KN, Kumar SK, Broski SM (2020) Role of imaging in multiple myeloma. Am J Hematol 95:966\u2013977. https:\/\/doi.org\/10.1002\/ajh.25846","journal-title":"Am J Hematol"},{"key":"5888_CR10","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Blad\u00e9 J, Mateos MV, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau JL, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajkumar SV, Miguel JS, Avet-Loiseau H (2016) International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17:e328\u2013e346. https:\/\/doi.org\/10.1016\/S1470-2045(16)30206-6","journal-title":"Lancet Oncol"},{"key":"5888_CR11","doi-asserted-by":"publisher","first-page":"8","DOI":"10.6004\/jnccn.2022.0002","volume":"20","author":"NS Callander","year":"2022","unstructured":"Callander NS, Baljevic M, Adekola K, Anderson LD, Campagnaro E, Castillo JJ, Costello C, Devarakonda S, Elsedawy N, Faiman M, Garfall A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Hultcrantz M, Kang Y, Larson S, Liedtke M, Martin T, Omel J, Sborov D, Shain K, Stockerl-Goldstein K, Weber D, Berardi RA, Kumar R, Kumar SK (2022) NCCN Guidelines\u00ae insights: multiple myeloma, Version 3.2022. J Natl Compr Canc Netw 20:8\u201319. https:\/\/doi.org\/10.6004\/jnccn.2022.0002","journal-title":"J Natl Compr Canc Netw"},{"key":"5888_CR12","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/bjh.14827","volume":"178","author":"A Chantry","year":"2017","unstructured":"Chantry A, Kazmi M, Barrington S, Goh V, Mulholland N, Streetly M, Lai M, Pratt G, British Society for Haematology Guidelines (2017) Guidelines for the use of imaging in the management of patients with myeloma. Br J Haematol 178:380\u2013393. https:\/\/doi.org\/10.1111\/bjh.14827","journal-title":"Br J Haematol"},{"key":"5888_CR13","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1182\/bloodadvances.2020004131","volume":"5","author":"M Kaddoura","year":"2021","unstructured":"Kaddoura M, Dingli D, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Kapoor P, Hwa L, Fonder A, Hobbs M, Hayman S, Lust J, Leung N, Go RS, Lin Y, Gonsalves W, Kourelis T, Warsame R, Kyle RA, Broski SM, Rajkumar V, Kumar S (2021) Prognostic impact of posttransplant FDG PET\/CT scan in multiple myeloma. Blood Adv 5:2753\u20132759. https:\/\/doi.org\/10.1182\/bloodadvances.2020004131","journal-title":"Blood Adv"},{"key":"5888_CR14","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1007\/s00259-017-3909-8","volume":"45","author":"C Nanni","year":"2018","unstructured":"Nanni C, Versari A, Chauvie S, Bertone E, Bianchi A, Rensi M, Bell\u00f2 M, Gallamini A, Patriarca F, Gay F, Gamberi B, Ghedini P, Cavo M, Fanti S, Zamagni E (2018) Interpretation criteria for FDG PET\/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe). Eur J Nucl Med Mol Imaging 45:712\u2013719. https:\/\/doi.org\/10.1007\/s00259-017-3909-8","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5888_CR15","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1200\/JCO.2017.72.2975","volume":"35","author":"P Moreau","year":"2017","unstructured":"Moreau P, Attal M, Caillot D, Macro M, Karlin L, Garderet L, Facon T, Benboubker L, Escoffre-Barbe M, Stoppa AM, Laribi K, Hulin C, Perrot A, Marit G, Eveillard JR, Caillon F, Bodet-Milin C, Pegourie B, Dorvaux V, Chaleteix C, Anderson K, Richardson P, Munshi NC, Avet-Loiseau H, Gaultier A, Nguyen JM, Dupas B, Frampas E, Kraeber-Bodere F (2017) Prospective Evaluation of Magnetic Resonance Imaging and [(18)F]Fluorodeoxyglucose Positron Emission Tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM\/DFCI 2009 Trial: results of the IMAJEM Study. J Clin Oncol 35:2911\u20132918. https:\/\/doi.org\/10.1200\/JCO.2017.72.2975","journal-title":"J Clin Oncol"},{"key":"5888_CR16","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1080\/10428194.2018.1459602","volume":"60","author":"B Jamet","year":"2019","unstructured":"Jamet B, Bailly C, Carlier T, Planche L, Touzeau C, Kraeber-Bod\u00e9r\u00e9 F, Moreau P, Bodet-Milin C (2019) Added prognostic value of FDG-PET\/CT in relapsing multiple myeloma patients. Leuk Lymphoma 60:222\u2013225. https:\/\/doi.org\/10.1080\/10428194.2018.1459602","journal-title":"Leuk Lymphoma"},{"key":"5888_CR17","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12880-022-00788-4","volume":"22","author":"R Zukovs","year":"2022","unstructured":"Zukovs R, Antke C, Mamlins E, Sawicki LM, Mohring A, Lopez Y, Niedenhoff D, Boquoi A, Kondakci M, Antoch G, M\u00fcller HW, Fenk R, Haas R (2022) 18F-FDG-PET\/CT in relapsed multiple myeloma: are prognostic thresholds different from first-line therapy? BMC Med Imaging 22:63. https:\/\/doi.org\/10.1186\/s12880-022-00788-4","journal-title":"BMC Med Imaging"},{"key":"5888_CR18","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1097\/RLU.0000000000000629","volume":"40","author":"EG de Waal","year":"2015","unstructured":"de Waal EG, Slart RH, Leene MJ, Kluin PM, Vellenga E (2015) F-18-FDG PET increases visibility of bone lesions in relapsed multiple myeloma is this Hypoxia-Driven? Clin Nucl Med 40:291\u2013296. https:\/\/doi.org\/10.1097\/RLU.0000000000000629","journal-title":"Clin Nucl Med"},{"key":"5888_CR19","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1007\/s00259-015-3200-9","volume":"43","author":"C Nanni","year":"2016","unstructured":"Nanni C, Zamagni E, Versari A, Chauvie S, Bianchi A, Rensi M, Bell\u00f2 M, Rambaldi I, Gallamini A, Patriarca F, Gay F, Gamberi B, Cavo M, Fanti S (2016) Image interpretation criteria for FDG PET\/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian myeloma criteria for PET USe). Eur J Nucl Med Mol Imaging 43:414\u2013421. https:\/\/doi.org\/10.1007\/s00259-015-3200-9","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5888_CR20","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, Verzijlbergen FJ, Barrington SF, Pike LC, Weber WA, Stroobants S, Delbeke D, Donohoe KJ, Holbrook S, Graham MM, Testanera G, Hoekstra OS, Zijlstra J, Visser E, Hoekstra CJ, Pruim J, Willemsen A, Arends B, Kotzerke J, Bockisch A, Beyer T, Chiti A, Krause BJ (2015) FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 42:328\u2013354. https:\/\/doi.org\/10.1007\/s00259-014-2961-x. European Association of Nuclear Medicine (EANM)","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5888_CR21","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/leu.2015.356","volume":"30","author":"J Laubach","year":"2016","unstructured":"Laubach J, Garderet L, Mahindra A, Gahrton G, Caers J, Sezer O, Voorhees P, Leleu X, Johnsen HE, Streetly M, Jurczyszyn A, Ludwig H, Mellqvist UH, Chng WJ, Pilarski L, Einsele H, Hou J, Turesson I, Zamagni E, Chim CS, Mazumder A, Westin J, Lu J, Reiman T, Kristinsson S, Joshua D, Roussel M, O\u2019Gorman P, Terpos E, McCarthy P, Dimopoulos M, Moreau P, Orlowski RZ, Miguel JS, Anderson KC, Palumbo A, Kumar S, Rajkumar V, Durie B, Richardson PG (2016) Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group. Leukemia 30:1005\u20131017. https:\/\/doi.org\/10.1038\/leu.2015.356","journal-title":"Leukemia"},{"key":"5888_CR22","doi-asserted-by":"publisher","first-page":"7381","DOI":"10.18632\/oncotarget.2290","volume":"5","author":"C Lapa","year":"2014","unstructured":"Lapa C, L\u00fcckerath K, Malzahn U, Samnick S, Einsele H, Buck AK, Herrmann K, Knop S (2014) (18)FDG-PET\/CT for prognostic stratification of patients with multiple myeloma relapse after stem cell transplantation. Oncotarget 5:7381\u20137391. https:\/\/doi.org\/10.18632\/oncotarget.2290","journal-title":"Oncotarget"},{"key":"5888_CR23","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.6004\/jnccn.2020.7673","volume":"18","author":"LJ Costa","year":"2020","unstructured":"Costa LJ, Usmani SZ (2020) Defining and managing high-risk multiple myeloma: current concepts. J Natl Compr Canc Netw 18:1730\u20131737. https:\/\/doi.org\/10.6004\/jnccn.2020.7673","journal-title":"J Natl Compr Canc Netw"},{"key":"5888_CR24","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"NWCJ van de Donk","year":"2021","unstructured":"van de Donk NWCJ, Pawlyn C, Yong KL (2021) Multiple myeloma. Lancet 397:410\u2013427. https:\/\/doi.org\/10.1016\/S0140-6736(21)00135-5","journal-title":"Lancet"},{"key":"5888_CR25","doi-asserted-by":"publisher","first-page":"4323","DOI":"10.3390\/cancers13174323","volume":"13","author":"G Fouquet","year":"2021","unstructured":"Fouquet G, Wartski M, Dechmi A, Willems L, Deau-Fischer B, Franchi P, Descroocq J, Deschamps P, Blanc-Autran E, Clerc J, Bouscary D, Barreau S, Chapuis N, Vignon M, Cottereau AS (2021) Prognostic value of FDG-PET\/CT parameters in patients with Relapse\/Refractory multiple myeloma before Anti-CD38 based Therapy. Cancers (Basel) 13:4323. https:\/\/doi.org\/10.3390\/cancers13174323","journal-title":"Cancers (Basel)"},{"key":"5888_CR26","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.remnie.2023.03.002","volume":"42","author":"AO Oner","year":"2023","unstructured":"Oner AO, \u00d6zdemir \u00c7, Yava\u015fo\u011flu F, \u015eenol Y, Ads\u0131z SN (2023) The relationship between immunohistochemical parameters, bone marrow fibrosis and bone marrow 18F-FDG uptake in multiple myeloma patients undergoing PET\/CT examination. Rev Esp Med Nucl Imagen Mol (Engl Ed) 42:289\u2013295. https:\/\/doi.org\/10.1016\/j.remnie.2023.03.002","journal-title":"Rev Esp Med Nucl Imagen Mol (Engl Ed)"},{"key":"5888_CR27","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.3324\/haematol.2021.278779","volume":"106","author":"D Baker","year":"2021","unstructured":"Baker D, Bimali M, Carrillo L, Sachedina A, Alapat D, Hoque MS, Kottarathara M, Parikh R, Erra A, Mitma AA, Mathur P, Ogunsesan Y, Yarlagadda L, Gundarlapalli S, Thanendrarajan S, Zangari M, Van Rhee F, Tricot G, Schinke C (2021) Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PETCT and minimal residual disease status. Haematologica 106:3215\u20133218. https:\/\/doi.org\/10.3324\/haematol.2021.278779","journal-title":"Haematologica"},{"key":"5888_CR28","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.3390\/cancers12092399","volume":"12","author":"X Zhou","year":"2020","unstructured":"Zhou X, Dierks A, Kertels O, Samnick S, Kircher M, Buck AK, Haertle L, Knorz S, B\u00f6ckle D, Scheller L, Messerschmidt J, Barakat M, Truger M, Haferlach C, Einsele H, Rasche L, Kort\u00fcm KM, Lapa C (2020) The link between Cytogenetics\/Genomics and Imaging Patterns of Relapse and Progression in patients with Relapsed\/Refractory multiple myeloma: a pilot study utilizing 18F-FDG PET\/CT. Cancers (Basel) 12:2399. https:\/\/doi.org\/10.3390\/cancers12092399","journal-title":"Cancers (Basel)"},{"key":"5888_CR29","doi-asserted-by":"publisher","first-page":"4517","DOI":"10.1038\/s41467-022-32145-y","volume":"13","author":"L Rasche","year":"2022","unstructured":"Rasche L, Schinke C, Maura F, Bauer MA, Ashby C, Deshpande S, Poos AM, Zangari M, Thanendrarajan S, Davies FE, Walker BA, Barlogie B, Landgren O, Morgan GJ, van Rhee F, Weinhold N (2022) The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states. Nat Commun 13:4517. https:\/\/doi.org\/10.1038\/s41467-022-32145-y","journal-title":"Nat Commun"},{"key":"5888_CR30","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41408-022-00732-3","volume":"12","author":"TE Long","year":"2022","unstructured":"Long TE, Indridason OS, Palsson R, Rognvaldsson S, Love TJ, Thorsteinsdottir S, Sverrisdottir IS, Vidarsson B, Onundarson PT, Agnarsson BA, Sigurdardottir M, Thorsteinsdottir I, Olafsson I, Thordardottir AR, Eythorsson E, Jonsson A, Gislason G, Olafsson A, Steingrimsdottir H, Hultcrantz M, Durie BGM, Harding S, Landgren O, Kristinsson SY (2022) Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study. Blood Cancer J 12:133. https:\/\/doi.org\/10.1038\/s41408-022-00732-3","journal-title":"Blood Cancer J"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05888-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05888-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05888-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T09:05:21Z","timestamp":1729933521000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05888-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,16]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["5888"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05888-5","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2024,7,16]]},"assertion":[{"value":"3 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}